Shows & Panels
- Accelerate and Streamline for Better Customer Service
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Client Virtualization Solutions
- Data Protection in a Virtual World
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Feds in the Cloud
- Health IT: A Policy Change Agent
- IT Innovation in the New Era of Government
- Making Dollars And Sense Out of Data Center Consolidation
- Navigating the Private Cloud
- One Step to the Cloud, Two Steps Toward Innovation
- Path to FDCCI Compliance
- Take Command of Your Mobility Initiative
Shows & Panels
FDA approves first-of-a-kind seasonal flu vaccine
Tuesday - 11/20/2012, 5:52pm EST
WASHINGTON (AP) - The Food and Drug Administration says it has approved the first seasonal flu vaccine made using animal cell technology, rather than the half-century egg method.
The FDA approved Novartis' Flucelvax to prevent influenza in people 18 years and older.
The new method has been promoted by U.S. health officials because it is faster than egg-based production and could speed up manufacturing in the event of a pandemic.
In the older method, virus samples are injected into specialized chicken eggs and incubated. The egg fluids are later harvested, concentrated and purified into the vaccine.
With cell technology, small amounts of virus are put in fermenting tanks with nutrients and cells derived from mammals. The virus is then inactivated, purified and put into vaccine vials.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)